Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, Tolerability, Biomarkers and Pharmacokinetics of Ibudilast (MN-166) in COVID-19 Subjects at Risk for Developing Acute Respiratory Distress Syndrome
Sponsor: MediciNova
A PHASE2 clinical study on Pneumonia, Viral, this trial is completed. The trial is conducted by MediciNova and has accumulated 14 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
14 versions recorded-
Nov 2024 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Apr 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE2
▶ Show 9 earlier versions
-
Sep 2022 — Apr 2023 [monthly]
Active Not Recruiting PHASE2
-
May 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2021 — May 2022 [monthly]
Recruiting PHASE2
-
Mar 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2020 — Nov 2020 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- MediciNova
For direct contact, visit the study record on ClinicalTrials.gov .